CTOs on the Move

Triosyn Research Inc

www.triosyn.com

 
Triosyn Research Inc is a Mirabel, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.triosyn.com
  • 14163 boul du Curķ©-Labelle
    Mirabel, QC CAN J7J 1M3
  • Phone: 450.434.6099

Executives

Name Title Contact Details

Similar Companies

Kaken Pharmaceuticals

Kaken Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACIĀ® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. EpicelĀ® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

Response Genetics

Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The KPC Group

The KPC Group is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease